A novel deletion variant in CLN3 with highly variable expressivity is responsible for juvenile neuronal ceroid lipofuscinoses

Author(s):  
Naser Gilani ◽  
Ehsan Razmara ◽  
Mehmet Ozaslan ◽  
Ihsan Kareem Abdulzahra ◽  
Saeid Arzhang ◽  
...  
2002 ◽  
Vol 2 (5) ◽  
pp. 423-437 ◽  
Author(s):  
Sandra Hofmann ◽  
Armita Atashband ◽  
Steve Cho ◽  
Amit Das ◽  
Praveena Gupta ◽  
...  

Data in Brief ◽  
2021 ◽  
pp. 107188
Author(s):  
Katharina N. Russell ◽  
Nadia L. Mitchell ◽  
Martin P. Wellby ◽  
Graham K. Barrell ◽  
David N. Palmer

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
L. C. Schenkel ◽  
E. Aref-Eshghi ◽  
K. Rooney ◽  
J. Kerkhof ◽  
M. A. Levy ◽  
...  

Abstract Background Phelan-McDermid syndrome is characterized by a range of neurodevelopmental phenotypes with incomplete penetrance and variable expressivity. It is caused by a variable size and breakpoint microdeletions in the distal long arm of chromosome 22, referred to as 22q13.3 deletion syndrome, including the SHANK3 gene. Genetic defects in a growing number of neurodevelopmental genes have been shown to cause genome-wide disruptions in epigenomic profiles referred to as epi-signatures in affected individuals. Results In this study we assessed genome-wide DNA methylation profiles in a cohort of 22 individuals with Phelan-McDermid syndrome, including 11 individuals with large (2 to 5.8 Mb) 22q13.3 deletions, 10 with small deletions (< 1 Mb) or intragenic variants in SHANK3 and one mosaic case. We describe a novel genome-wide DNA methylation epi-signature in a subset of individuals with Phelan-McDermid syndrome. Conclusion We identified the critical region including the BRD1 gene as responsible for the Phelan-McDermid syndrome epi-signature. Metabolomic profiles of individuals with the DNA methylation epi-signature showed significantly different metabolomic profiles indicating evidence of two molecularly and phenotypically distinct clinical subtypes of Phelan-McDermid syndrome.


iScience ◽  
2020 ◽  
pp. 102020
Author(s):  
Katharina Iwan ◽  
Robert Clayton ◽  
Philippa Mills ◽  
Barbara Csanyi ◽  
Paul Gissen ◽  
...  

Genes ◽  
2021 ◽  
Vol 12 (5) ◽  
pp. 706
Author(s):  
Angela Sparago ◽  
Flavia Cerrato ◽  
Laura Pignata ◽  
Francisco Cammarata-Scalisi ◽  
Livia Garavelli ◽  
...  

Beckwith-Wiedemann syndrome (BWS) is an imprinting disorder characterized by prenatal and/or postnatal overgrowth, organomegaly, abdominal wall defects and tumor predisposition. CDKN1C is a maternally expressed gene of the 11p15.5 chromosomal region and is regulated by the imprinting control region IC2. It negatively controls cellular proliferation, and its expression or activity are frequently reduced in BWS. In particular, loss of IC2 methylation is associated with CDKN1C silencing in the majority of sporadic BWS cases, and maternally inherited loss-of-function variants of CDKN1C are the most frequent molecular defects of familial BWS. We have identified, using Sanger sequencing, novel CDKN1C variants in three families with recurrent cases of BWS, and a previously reported variant in a woman with recurrent miscarriages with exomphalos. Clinical evaluation of the patients showed variable manifestation of the disease. The frameshift and nonsense variants were consistently associated with exomphalos, while the missense variant caused a less severe phenotype. Pregnancy loss and perinatal lethality were found in the families segregating nonsense mutations. Intrafamilial variability of the clinical BWS features was observed, even between siblings. Our data are indicative of severe BWS phenotypes that, with variable expressivity, may be associated with both frameshift and nonsense variants of CDKN1C.


2019 ◽  
Vol 46 (8) ◽  
Author(s):  
Ken Okamura ◽  
Yuko Abe ◽  
Masahiro Hayashi ◽  
Toru Saito ◽  
Kei Nagatani ◽  
...  

2015 ◽  
Vol 1852 (10) ◽  
pp. 2301-2311 ◽  
Author(s):  
Romina Kohan ◽  
Favio Pesaola ◽  
Norberto Guelbert ◽  
Patricia Pons ◽  
Ana María Oller-Ramírez ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document